Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Obesity Medicine
•
Primary Care
How do you decide whether to reinitiate a GLP-1 agonist after a patient has experienced acute pancreatitis while on this therapy?
Answer from: at Community Practice
Will not try it again, given the seriousness of the side effect, and in most cases, there are alternatives.
Sign In
or
Register
to read more
27578
Related Questions
How do you counsel patients on GLP-1 agonists for weight loss who wish to space out their medication or take a "drug holiday" to temporarily increase their appetite?
How do you discuss the role (if there is any) of frequently weighing yourself at home for patients who desire weight loss?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?
Do you routinely check vitamin K levels in post-bariatric surgery patients?
What strategies do you recommend to address the negative self-talk/internalized bias that patients carry about their own weight?
What false positive findings, if any, do you see in patients who have active hepatitis C?
Is it safe to prescribe Invokana or Metformin for patients taking Biktarvy?
What is your preferred method for latent tuberculosis screening prior to outpatient hemodialysis initiation for a patient with new dialysis requirements?